Global Triptorelin Market - 2020-2027
|Triptorelin的全球市場(2020年∼2027年) Global Triptorelin Market - 2020-2027|
|出版日期: 按訂單生產||內容資訊: 英文||
The global triptorelin market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). It was first registered in France in 1986, is currently marketed in more than 80 countries and is leading market in many territories globally. In the US, triptorelin is registered as Trelstar for prostate cancer.
Triptorelin is a peptide formulation for injection which was developed mainly for the treatment of advanced metastatic prostate cancer. Also, other indications developed subsequently include the treatment of uterine fibroids (a benign tumour of muscle tissues in the uterus), endometriosis prior to surgery, and early-onset puberty and female infertility (in vitro fertilization).
Another common use of triptorelin is for hormone replacement therapy to suppress testosterone or estrogen levels in the transgender people (in conjunction with estradiol valerate for trans women or testosterone for trans men). Cyproterone and Spironolactone acetate are other drugs used by many trans people to suppress sex hormones. Triptorelin has been used as a chemical castration agent for reducing sexual urges in sex offenders.
Increasing R&D in triptorelin for various therapeutic indications is driving the market growth
Increasing research and development in triptorelin for applications in various therapeutic indications, by private manufacturers and research organizations is driving the growth of the market. Several clinical trials are undergoing to expand the potential future application of triptorelin in breast cancer and Human Immunodeficiency Virus (HIV). Also, the wide application of triptorelin in prostate cancer, salivary gland cancer, and central precious puberty are expected to fuel the growth of the market during the forecast period. Furthermore, higher efficacy and tolerability of triptorelin in the suppression of gonadotropin secretion in prostate cancer and precocious puberty is increasing adoption of triptorelin in the market.
Development of products by major manufacturers to expand their presence globally is also boosting the market growth
Pharmaceutical manufacturers of triptorelin products are updating their product portfolio by implementing inorganic growth strategies to sustain their foothold in the market. For instance, in June 2019, Debiopharm and Ipsen announced the renewal of their Decapeptyl agreement, which extends and strengthens their strategic partnership through 2034 for the development, manufacturing and distribution of Decapeptyl across Europe and certain Asian and African markets.
In October 2017, Arbor Pharmaceuticals, LLC and Debiopharm International SA made commercially available Triptodur (triptorelin), in the U.S. for the treatment of pediatric patients two years and older diagnosed with Central Precocious Puberty (CPP).
Also, in January 2016, both the companies jointly announced the execution of a distribution agreement for the commercialization and promotion of triptorelin 22.5 mg in the U.S. for central precocious puberty (CPP).
Side effects asscoated with Triptorelin are likely to hamper the market growth
Triptorelin has some side effects which might hamper the growth of the market. Some of the general side effects include anaphylaxis, arthralgia, asthenia, asthma, breast tenderness (males and females), changes in blood pressure, changes in breast size, depression, ovarian cysts, mood changes, skin rashes, hot flushes, among others.
COVID-19 Impact Analysis
The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets. The global triptorelin market has slowed down from the COVID-19 pandemic, as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by the COVID-19.
The global Triptorelin market is segmented on the basis of drug type, application, and distribution channel.
By Drug type, Triptorelin Pamoate is expected to witness rapid growth
On the basis of drug type, the triptorelin market is segmented into triptorelin pamoate, triptorelin acetate, and triptorelin embonate. Among these, the triptorelin pamoate is expected to grow at the fastest growth rate during the forecast period. Debiopharm has developed three sustained-release formulations (one, three and six months) of triptorelin pamoate.
Triptorelin is marketed under different brand names such as Decapeptyl (Ipsen) and Diphereline and Gonapeptyl (Ferring Pharmaceuticals). In the United States, it is sold as Trelstar by Watson Pharmaceuticals and as Triptodur (an extended-release 6-month depot injection) by Arbor Pharmaceuticals. In Iran, triptorelin is marketed under the brand name Variopeptyl.
Triptodur is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of pediatric patients two years and older with central precocious puberty. Triptodur is for extended-release injectable suspension, for intramuscular use.
By application, Prostate Cancer is dominating the maximum market share
Prostate cancer is one of the most common cancers in American men, and this is made apparent by the statistics surrounding it. It is estimated by the American Cancer Society that in 2019 there will be about 174,650 men with newly diagnosed prostate cancer which is a 6% increase from 2018. There will also be an estimated 31,620 deaths from prostate cancer in 2019, a 7% increase from 2018. According to Zero Cancer, every 17 minutes, another man in the U.S. dies from prostate cancer, which is about 86 deaths per day. The number of deaths are increasing year after year, making prostate cancer the second leading cause of cancer death in men in the United States.
Triptorelin is used to treat prostate cancer (PCa) as part of androgen deprivation therapy (ADT). Another ADT injectable medicine commonly used to treat PCa includes Lupron, which also targets the pituitary. Other modalities of triptorelin such as triptorelin acetate, triptorelin pamoate and triptorelin embonate are also used for prostate cancer treatment.
North America region holds the largest market share in the global Triptorelin market
North America region is dominating the global Triptorelin market accounted for the largest market share in 2019, owing to rising incidence of prostate cancer and salivary gland cancer and growing prevalence of central precocious puberty among the young patients below age of eight and nine years. For instance, as per the National Organization for Rare Disorders (NORD), the Central Precocious Puberty (CPP), accounting for about 1 to 5 in 10,000 children with a female to male ratio of about 20:1, in the U.S.
Europe is the second largest market in the global triptorelin market
Europe triptorelin market growth is attributable to due to growing prevalence of prostate cancer, increasing approvals of drugs for different indications in european countries. For instnace, In March 2017, Debiopharm International, a Swiss-based company, part of Debiopharm Group, announced that triptorelin 6-month formulation (Decapeptyl and Pamorelin 22.5 mg) received approval for the treatment of central precocious puberty (CPP) in 22 European countries, where the 6-month formulation has already been registered for the treatment of prostate cancer.
Also, in March 2017, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, in coordination with fourteen other European regulatory agencies approved a new indication of Decapeptyl (triptorelin). As per these new indication, Decapeptyl (triptorelin) is used as adjuvant treatment in combination with tamoxifen or aromatase inhibitor for endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy. This would enhance the revenue for growth for triptorelin market in Europe over the forecast period.
Also, in August 2016, Teva Pharmaceutical Industries Ltd. completed the acquisition of Allergan's generics business: Actavis Generics. This strategic acquisition combines two leading generic business with complementary strengths, research and development (R&D) capabilities, product pipeline and portfolio, operational expertise and also help to harness geographical footprint capabilities.
The major players in the market are engaged in expanding their product portfolio in various geographical areas. For instance, in January 2019, Debiopharm Group announced an agreement with Allergan to initiate a transition process for Trelstar (Triptorelin pamoate) intended to lead to new licensees taking over the commercialization of Trelstar in the U.S. and Canada and the termination of Allergan's partnership with Debiopharm for strategic reasons.
The Triptorelin market is moderately competitive. The rising drug development may witness the entry of few small- or mid-sized companies in the market during the forecast period. Some of the key players which are contributing to the growth of the market include Ipsen, Debiopharm Group, Bachem , Ferring Pharmaceuticals Pvt Ltd., Chengdu Tiantaishan pharmaceutical Co., Ltd., Tecnofarma, Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.), Arbor Pharmaceuticals, LLC, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the triptorelin market globally.
Debiopharm Group is a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management. Debiopharm focuses on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.
Debiopharm has developed three sustained-release formulations (1, 3 and 6 months) of triptorelin pamoate.
Decapeptyl®/Trelstar®/Pamorelin®/Triptodur®, is a GnRH agonist analogue. An agonist is a chemical that binds to a receptor of a cell and triggers a response by that cell. Triptorelin decreases the serum testosterone to castrate levels (estradiol in females).
The global triptorelin market report would provide an access to an approx. 58 market data table, 55 figures and 220 pages.
LIST NOT EXHAUSTIVE